We have continued the expansion of our product portfolio and global reach, with the 18th, 19th and 20th acquisitions in Dechra’s history.
Acquisitions
Ampharmco
Acquisition date:
August 2019
Cost of acquisition:
$29.6 million
Key benefits of acquisition:
- Acquisition of manufacturing facilities to establish a US manufacturing base for Dechra
- Addition of CAP portfolio products
Mirataz
Acquisition date:
April 2020
Cost of acquisition:
$43 million
(excluding royalty fees)
Key benefits of acquisition:
- First and only FDA and EMA approved transdermal medication for management of weight loss in cats
- A new global brand to add to the Dechra portfolio marketed in US and licensed in all EU markets. Registered in 32 countries globally
Osurnia
Acquisition date:
July 2020
Cost of acquisition:
$135 million
Key benefits of acquisition:
- Acquisition of a long-acting treatment of otitis externa in dogs
- New global leading brand to add to Dechra portfolio
- Registered in 51 countries around the world